Merck’s KEYTRUDA shows significant survival boost in platinum-resistant ovarian cancer
KEYTRUDA had previously met its primary endpoint of progression-free survival in all patients
KEYTRUDA had previously met its primary endpoint of progression-free survival in all patients
The TacroType test provides actionable genetic insights to help clinicians understand how individual patients metabolize tacrolimus
Zongertinib is setting a new standard as the first targeted therapy for treatment naïve patients with HER2-mutant advanced non-small cell lung cancer with demonstrated efficacy
The oral therapy is aimed at adults with chronic spontaneous urticaria (CSU) who do not respond adequately to H1-antihistamines
The initiative, funded entirely under the company’s CSR programme, is expected to reach over a million lives
The company said the move applies to all doses and reflects its commitment to making its medicines more affordable for patients
Asahi Kasei Pharma receives worldwide exclusive rights for the research, development, manufacturing, and marketing of the active ingredients
For the fourth quarter, revenue surged 47% year-on-year to Rs. 2,510 million, driven by a 23% rise in domestic sales and a 9.3x jump in export sales
Arcellx develops innovative immunotherapies for cancer and other incurable diseases
Subscribe To Our Newsletter & Stay Updated